Sustained release delivery system

A sustained release kit comprising a plurality of sustained release mini tablet implants packaged for delivery in a single treatment,

• each mini tablet implant comprising
• a pharmaceutically active composition comprising
• at least one pharmaceutically active component;
• and
• a carrier therefor;
• wherein the carrier is a sugar or mineral salt or mixture thereof,
• wherein each mini tablet implant is of the coated tablet type;
• each mini tablet implant being approximately 0.1 to 0.5 times the length and/or diameter of a single immediate release tablet capable of providing the desired threshold blood level depending on the pharmaceutically active component selected, and
• having a payload of approximately 30% to 70% by weight of the total payload of an equivalent immediate release treatment conducted for an equivalent period;
• the sustained release apparatus providing, in use, zero order release of pharmaceutically active component;
• each mini-tablet implant being of insufficient size and/or payload individually to provide a predetermined desired threshold blood level of pharmaceutically active component for treatment of a selected indication.

A sustained release anthelmintic apparatus comprising a plurality of sustained release compressed mini tablet implants;

• each mini tablet implant comprising
• an anthelmintic pharmaceutical composition comprising
• an anthelmintic component;
• and
• a non-silicone carrier therefor and
• an anthelmintic pharmaceutical composition comprising
• at least one anthelmintic pharmaceutical component;
• and
• a carrier therefor;
• wherein the carrier is a sugar or mineral acid or mixture thereof,
• wherein each mini tablet implant is of the coated tablet type;
• each mini tablet implant being approximately 0.1 to 0.5 times the length and/or diameter of a single immediate release tablet capable of providing the desired threshold blood level depending on the anthelmintic pharmaceutical component selected, and
• having a payload of approximately 30% to 70% by weight of the total payload of an equivalent immediate release treatment conducted for an equivalent period;
• the sustained release apparatus providing, in use, zero order release of anthelmintic pharmaceutical component;
• each mini-tablet implant being of insufficient size and/or payload individually to provide a predetermined desired threshold blood level of pharmaceutically active component for treatment of a selected indication.

A method for the therapeutic or prophylactic treatment of a parasitic infection or a growth-related indication in an animal requiring such treatment, which method comprises administering to the animal a sustained release delivery apparatus comprising a plurality of sustained release mini tablet implants;

• each mini tablet implant comprising
• a pharmaceutically active composition comprising
• an anti-parasitic active or a growth-enhancing component;
• and
• a carrier therefor a carrier therefor;
• wherein the carrier is a sugar or mineral salt or mixture thereof,
• wherein each mini tablet implant is of the coated tablet type;
• each mini tablet implant being approximately 0.1 to 0.5 times the length and/or diameter of a single immediate release tablet capable of providing the desired threshold blood level depending on the pharmaceutical active component selected, and
• having a payload of approximately 30% to 70% by weight of the total payload of an equivalent immediate release treatment conducted for an equivalent period;
• the sustained release apparatus providing, in use, zero order release of pharmaceutical active component;
• each mini tablet implant being of insufficient size and/or payload individually to provide a predetermined required threshold blood level of pharmaceutically active component for treatment of a selected indication.